DB05776InvestigationalProtein Based Therapies
IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C. The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426)...
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C).Curator reviewed
What you can answer from here — as of April 02, 2025
Which companies are running trials of IC41, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account